论文部分内容阅读
介绍一种新的小细胞肺癌的肿瘤标志物。用基因重组的人胃泌素释放肽前体 (pro gas trin releasingpeptide ,ProGRP)制备单克隆抗体和抗血清 ,建立ProGRP的双抗体夹心酶联免疫检测 (ELISA)方法。临床实验研究显示该检测方法对小细胞肺癌诊断的特异性高 ,对早期小细胞肺癌也有较高的阳性率 ,检测的可靠性也很高。各种临床实验结果也证明 ,ProGRP是临床诊断和鉴别诊断小细胞肺癌的良好的肿瘤标志物 ,而且ProGRP比神经元特异烯醇化酶更适宜用于小细胞肺癌的早期诊断。新近有学者发现在需要血液透析的慢性肾功能衰竭患者中有 96%血清ProGRP超过临界值。因此在临床应用ProGRP免疫检测作为小细胞肺癌的诊断和判断疗效和复发时 ,必须检查患者的肾功能以排除慢性肾功能衰竭所出现的血中ProGRP的升高。
Introduce a new tumor marker for small cell lung cancer. Monoclonal antibody and antiserum were prepared using the recombinant pro gas trin releasing peptide (ProGRP), and a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) method for ProGRP was established. Clinical trials have shown that this assay has a high specificity for the diagnosis of small cell lung cancer and a high positive rate for early stage small cell lung cancer. The detection reliability is also high. Various clinical trials also proved that ProGRP is a good tumor marker for clinical diagnosis and differential diagnosis of small cell lung cancer, and ProGRP is more suitable for the early diagnosis of small cell lung cancer than neuron-specific enolase. Newer scholars have found that 96% of patients with chronic renal failure requiring hemodialysis exceed the critical value of serum ProGRP. Therefore, in the clinical application of ProGRP immunodetection as a diagnosis of small cell lung cancer and judgement of efficacy and recurrence, the patient’s renal function must be examined to rule out the rise of blood ProGRP in chronic renal failure.